Pfizer Strikes Deal with China’s 3SBio to License Cancer Drug

Pfizer strikes deal with China's 3SBio to license cancer drug

CNBC uses data from DealForma to report on Pfizer’s and China’s 3SBio’s deal to license cancer drug. Watch the clip here

DealForma Research

Explore More
Cancer R&D Partnerships, M&A and Venture Funding by Tech - Q1 2025 Review

Cancer R&D Partnerships, M&A and Venture Funding by Tech – Q1 2025 Review

Cancer R&D Partnerships, M&A and Venture Funding Activity by TA - Q1 2025

Cancer R&D Partnerships, M&A and Venture Funding Activity by TA – Q1 2025

MedTech, Device, Digital Health, and Wearables M&A and Ventures – Q1 2025

MedTech, Device, Digital Health, and Wearables M&A and Ventures – Q1 2025

All of this by stage, disease indication, modality, target…

Schedule your Demo
+ 0 k
Licensing Deals
+ 0 k
M&A
+ 0 k
Other Deals
+ 0 k
Funding Rounds
+ 0 k
Company Profiles
+ 0 k
Drug Sales Figures
DealForma Logo

DealForma is the biopharma deal database providing you comprehensive information and dedicated analyst support to help you be more confident using quality data in your business development research.

Linkedin

Database

Company

Comparisons

Website Design by Once Interactive